ICON Selected by the FDA for New PRO Measure

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced it has been awarded a project by the FDA to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).

HABP is the second most common hospital-acquired infection and is the primary cause of death in intensive care units.

The collaboration brings together scientists from ICON’s Commercialization and Outcomes group, FDA, the National Institute of Allergy and Infectious Diseases, the Infectious Diseases Society of America, pharmaceutical and biotechnology companies, and the academic research community to develop new approaches to evaluating the efficacy of antibiotics in future clinical trials of therapies for HABP.